Posts in News
FELDAN THERAPEUTICS SECURES $16.5M SERIES B TO BRING LEAD ASSET TO CLINICAL DEVELOPMENT

QUÉBEC CITY, June 13, 2023 /PRNewswire/ - Feldan Therapeutics, a biopharmaceutical company that specializes in the development of treatments based on intracellular delivery of therapeutics, has announced the initial closing of a $16.5 million Series B investment. The funds will primarily be used to conduct clinical phases I/II for Feldan's FLD-103, an intralesional treatment against basal cell carcinoma (BCC), and to advance its pulmonary program to the preclinical stage.

Read More
An additional boost to Aplantex’ innovative green biotechnology process

One of Aplantex’ technical partners, the Centre d’études des procédés chimiques du Québec (CEPROCQ) represented by Yacine Boumghar, Ph.D, has received a grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) to support the continued development of Aplantex’ innovative process to produce valuable molecules commonly used by the pharmaceutical, cosmetics, and agrifood industries.

Read More
Calder Biosciences announces clinical supply agreement with Biodextris to evaluate its lead RSV vaccine candidate as part of a Phase 1 clinical trial

BOSTON, June 6, 2023 /PRNewswire/ - Calder Biosciences Inc., a molecular engineering and clinical manufacturing-stage biotechnology company pioneering its 3D-Vaxlockä platform technology to engineer and develop novel protein subunit vaccines, today announced a clinical supply agreement with Biodextris Inc.

Read More
Merck Canada reaffirms its commitment to CQDM with $3M in funding to support biopharmaceutical innovation.

Boston, Massachusetts – June 5, 2023 – CQDM is delighted, at BIO2023, in the presence of Minister Fitzgibbon, Quebec’s Minister of the Economy, Innovation and Energy (MEIE) to announce that Merck Canada, has renewed its commitment to CQDM with $3.0M in funding to support the development of innovative technologies in biopharmaceutical research.

Read More
Over $5 million to accelerate cancer research and innovation in Quebec - Oncopole strengthens its leadership role in the oncology ecosystem with the support of numerous partners

MONTREAL and BOSTON, June 5, 2023 /CNW/ - Oncopole, Fonds de recherche du Québec - Santé (FRQS) cancer division, is proud to announce major investments that bolster its unique public-private partnership model dedicated to the fight against cancer. Building on its dynamism and ability to mobilize stakeholders in the life sciences community, Oncopole will continue to pursue its mission thanks to a $3 million reinvestment from founding partner Merck Canada.

Read More
Biopharma company GSK grants $1 million to Halifax-based Canadian Center for Vaccinology (CCfV)

Grant recognizes CCfV's national leadership and Nova Scotian contribution to Canada's research capabilities, expected to attract top talent.

MISSISSAUGA, ON, May 31, 2023 /CNW/ - GSK announces a $1 million grant to strengthen the Canadian Center for Vaccinology (CCfV)'s position in the national infectious disease research landscape. The private funding will be a catalyst for growth of the Halifax-based centre, increasing employment opportunities and bolstering top-quality research and pandemic preparedness locally and nationally.

Read More
Novartis Canada launches new head office in the Health Innovation District of Montréal, featuring a unique environment to inspire co-creation, partnerships and continued healthcare innovation

creation and exchange of innovative ideas.

Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce the official opening of its new Montréal office in the heart of Old Montréal. Located in the iconic Place Gare Viger, the office has been designed to provide a modern workplace that meets the needs of Novartis' associates and facilitates closer collaboration with key stakeholders.

Read More
enGene, Inc. and Forbion European Acquisition Corp. Announce Business Combination Agreement to Create Biotechnology Company

enGene, Inc. (“enGene”), a clinical-stage biotechnology company pioneering novel non-viral gene therapies for local administration into mucosal tissues, and Forbion European Acquisition Corp. (“FEAC,” Nasdaq: FRBN), a special purpose acquisition company, today announced that they have entered into a definitive business combination agreement. Upon closing of the transaction, the combined company will be named “enGene Holdings Inc.” whose common shares are expected to be listed on Nasdaq.

Read More
CATTI opens a cell and gene therapy training centre of excellence at the University of Guelph

The Canadian Advanced Therapies Training Institute (CATTI) Inc. has launched its first in-person training site at the University of Guelph through a partnership with OmniaBio Inc., CCRM and the university. The training program, to begin in summer 2023, will cater to recent post-secondary graduates, industry professionals and companies growing their roster of clean room manufacturing staff. The fast growth of cell and gene therapies (CGTs) has made it a challenge for the global industry to keep up with talent requirements. This new CGT technical training site will begin to address the industry's critical training needs and represents the first stage of a larger, multi-site training strategy for CATTI.

Read More
BIOQuébec showcased in the Spring issue of BIOTECanada’S Insights Magazine

BIOQuébec: a powerful facilitator for your organization

When Anie Perrault, then executive director, met Frédéric Leduc for the first time in 2014, she convinced him to become a member by highlighting the benefits of a strong, extensive network and the possibility of makinghis voice heard via BIOQuébec. Frédéric immediately seized this unique opportunity to meet potential clients and collaborators for the young biotech he had co-founded.

Read More
Molecular Forecaster Participates in the $165-million CFREF grant awarded to McGill University to support its inclusive genomics and RNA research program

As a McGill University spinout company, we at Molecular Forecaster are thrilled to support the recent landmark government investment into our alma mater through “DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R)”. The $165M investment, bolstered by another $185M+ commitment from academic and industrial partners will go towards supporting fundamental RNA research, including drug discovery efforts, which aligns perfectly with our company's mission and values.

Read More
RYALTRIS®, a new combination prescription nasal spray for moderate to severe seasonal allergic rhinitis (SAR), now available across Canada

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) is pleased to announce the availability across Canada of its new prescription treatment RYALTRIS® (olopatadine hydrochloride and mometasone furoate nasal spray).

RYALTRIS has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older.

Read More
$165-million for McGill University’s world-leading inclusive genomics and RNA research program

McGill is the recipient of a landmark $165 million CFREF grant to launch DNA to RNA: An Inclusive Canadian Approach to Genomic-based RNA Therapeutics (D2R), a first-of-its-kind global research effort specializing in the development and delivery of more inclusive genomic-based RNA therapeutics. D2R will receive significant support from more than 50 partners, including many from academia and industry, who have all pledged to invest in the research, which brings the total amount invested in D2R to $353 million.

Read More